Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Myeloid Malignancy 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 17fludarabine 16fludarabine phosphate 11Azacitidine 9venetoclax 8Rituximab 8Nivolumab 7Melphalan 7Tacrolimus 6Cytarabine 6Specimen Handling 5Sirolimus 5Ipilimumab 5Clofarabine 5CTLA-4 Antigen 5Antilymphocyte Serum 5belinostat 4aldesleukin 4Thiotepa 4Standard of Care 4Practice Guidelines as Topic 4Mycophenolic Acid 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Busulfan 4Bortezomib 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Neoplasms × eprenetapopt × Clear all
NCT00900614 2019-07-31

Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

Aprea Therapeutics

Phase 1 Completed
36 enrolled
GenitourinaryOther hematologic neoplasm

Prostatic Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡